Dorval Allison, a director, made two open market stock sales over the last year with no purchases. He sold Verve Therapeutics ($VERV) shares once for $13,902.50 on April 2, 2025, ranking 11,186th among insiders by sale value. He also sold Puma Biotechnology ($PBYI) shares once for $39,474 on June 13, 2025, ranking 10,622nd. Among 11,678 insiders, the average sale totals about 8.6 million across 6.4 transactions.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| July 25, 2025 | Verve Therapeutics, Inc. | $VERV | Dorval Allison | Chief Financial Officer | D | Restricted Stock Units | 33750 | $0.00 | 0.0000 | 89,143,237 | 100.00% | 0.04% |
| July 25, 2025 | Verve Therapeutics, Inc. | $VERV | Dorval Allison | Chief Financial Officer | D | Restricted Stock Units | 45000 | $0.00 | 0.0000 | 89,143,237 | 100.00% | 0.05% |
| July 25, 2025 | Verve Therapeutics, Inc. | $VERV | Dorval Allison | Chief Financial Officer | D | Restricted Stock Units | 1875 | $0.00 | 0.0000 | 89,143,237 | 100.00% | 0.00% |
| July 25, 2025 | Verve Therapeutics, Inc. | $VERV | Dorval Allison | Chief Financial Officer | D | Stock Option (right to buy) | 180000 | $0.00 | 0.0000 | 89,143,237 | 100.00% | 0.20% |
| July 25, 2025 | Verve Therapeutics, Inc. | $VERV | Dorval Allison | Chief Financial Officer | U | Common Stock | 13280 | $0.00 | 0.0000 | 89,143,237 | 100.00% | 0.01% |
| July 25, 2025 | Verve Therapeutics, Inc. | $VERV | Dorval Allison | Chief Financial Officer | D | Stock Option (right to buy) | 258000 | $0.00 | 0.0000 | 89,143,237 | 100.00% | 0.29% |
| July 25, 2025 | Verve Therapeutics, Inc. | $VERV | Dorval Allison | Chief Financial Officer | D | Stock Option (right to buy) | 75000 | $0.00 | 0.0000 | 89,143,237 | 100.00% | 0.08% |
| June 13, 2025 | PUMA BIOTECHNOLOGY, INC. | $PBYI | Dorval Allison | Director | S | Common Stock | 11610 | $3.40 | 75,390.0000 | 49,100,433 | 13.34% | 0.02% |
| June 11, 2025 | PUMA BIOTECHNOLOGY, INC. | $PBYI | Dorval Allison | Director | A | Common Stock | 27000 | $0.00 | 87,000.0000 | 49,100,433 | 45.00% | 0.05% |
| April 2, 2025 | Verve Therapeutics, Inc. | $VERV | Dorval Allison | Chief Financial Officer | S | Common Stock | 3350 | $4.15 | 13,280.0000 | 88,795,768 | 20.14% | 0.00% |
| April 1, 2025 | Verve Therapeutics, Inc. | $VERV | Dorval Allison | Chief Financial Officer | M | Common Stock | 11250 | $0.00 | 16,630.0000 | 88,795,768 | 209.11% | 0.01% |
| April 1, 2025 | Verve Therapeutics, Inc. | $VERV | Dorval Allison | Chief Financial Officer | M | Restricted Stock Units | 11250 | $0.00 | 33,750.0000 | 88,795,768 | 25.00% | 0.01% |
| Jan. 8, 2025 | Verve Therapeutics, Inc. | $VERV | Dorval Allison | Chief Financial Officer | A | Stock Option (right to buy) | 258000 | $0.00 | 258,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 8, 2025 | Verve Therapeutics, Inc. | $VERV | Dorval Allison | Chief Financial Officer | A | Restricted Stock Units | 45000 | $0.00 | 45,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 8, 2025 | Verve Therapeutics, Inc. | $VERV | Dorval Allison | Chief Financial Officer | A | Stock Option (right to buy) | 75000 | $0.00 | 75,000.0000 | 0 | 9999.99% | 0.00% |
| Dec. 2, 2024 | Verve Therapeutics, Inc. | $VERV | Dorval Allison | Chief Financial Officer | S | Common Stock | 555 | $5.64 | 5,380.0000 | 0 | 9.35% | 0.00% |
| Nov. 29, 2024 | Verve Therapeutics, Inc. | $VERV | Dorval Allison | Chief Financial Officer | M | Restricted Stock Units | 1875 | $0.00 | 1,875.0000 | 0 | 50.00% | 0.00% |
| Nov. 29, 2024 | Verve Therapeutics, Inc. | $VERV | Dorval Allison | Chief Financial Officer | M | Common Stock | 1875 | $0.00 | 5,935.0000 | 0 | 46.18% | 0.00% |
| June 18, 2024 | PUMA BIOTECHNOLOGY, INC. | $PBYI | Dorval Allison | Director | A | Common Stock | 27000 | $0.00 | 60,000.0000 | 47,550,852 | 81.82% | 0.06% |
| June 13, 2024 | PUMA BIOTECHNOLOGY, INC. | $PBYI | Dorval Allison | Director | S | Common Stock | 11000 | $3.37 | 33,000.0000 | 47,550,852 | 25.00% | 0.02% |
| June 5, 2024 | Jade Biosciences, Inc. | $JBIO | Dorval Allison | Not found | A | Stock Option (Right to Buy) | 12500 | $0.00 | 12,500.0000 | 0 | 9999.99% | 0.00% |
| Feb. 14, 2024 | Verve Therapeutics, Inc. | $VERV | Dorval Allison | Chief Financial Officer | A | Stock Option (right to buy) | 180000 | $0.00 | 180,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 14, 2024 | Verve Therapeutics, Inc. | $VERV | Dorval Allison | Chief Financial Officer | A | Restricted Stock Units | 45000 | $0.00 | 45,000.0000 | 0 | 9999.99% | 0.00% |
| June 13, 2023 | PUMA BIOTECHNOLOGY, INC. | $PBYI | Dorval Allison | Director | A | Common Stock | 27000 | $0.00 | 44,000.0000 | 44,929,998 | 158.82% | 0.06% |
| June 13, 2023 | PUMA BIOTECHNOLOGY, INC. | $PBYI | Dorval Allison | Director | S | Common Stock | 10000 | $3.45 | 17,000.0000 | 44,929,998 | 37.04% | 0.02% |